Patient and transplant characteristics
| . | Patient mismatch HLA-DP group . | . | |||
|---|---|---|---|---|---|
| . | HLA-DP2 group (N = 657) . | HLA-DP5 group (N = 629) . | P . | ||
| Median patient age (range), y | 36 | (0-77) | 36 | (1-68) | .41 |
| Median donor age (range), y | 35 | (20-55) | 34 | (20-58) | .71 |
| Years of transplantation, no. (%) | |||||
| 1993-2000 | 204 | (31.1) | 197 | (31.3) | .92 |
| 2001-2005 | 247 | (37.6) | 230 | (36.6) | |
| 2006-2010 | 206 | (31.4) | 202 | (32.1) | |
| Patient-donor sex, no. (%) | |||||
| Male-male | 275 | (41.9) | 269 | (42.8) | .62 |
| Female-female | 115 | (17.5) | 109 | (17.3) | |
| Male-female | 167 | (25.4) | 143 | (22.7) | |
| Female-male | 100 | (15.2) | 108 | (17.2) | |
| Disease, no. (%) | |||||
| ALL | 201 | (30.6) | 189 | (30.0) | .99 |
| AML | 282 | (42.9) | 269 | (42.8) | |
| MDS | 85 | (12.9) | 82 | (13.0) | |
| CML | 89 | (13.5) | 89 | (14.1) | |
| Leukemia risk, no. (%) | |||||
| Standard | 383 | (58.3) | 324 | (51.5) | .05 |
| High | 242 | (36.8) | 272 | (43.2) | |
| Other | 32 | (4.9) | 33 | (5.2) | |
| GVHD prophylaxis, no. (%) | |||||
| Cyclosporine based | 294 | (44.7) | 294 | (46.7) | .56 |
| Tacrolimus based | 348 | (53.0) | 325 | (51.7) | |
| Other | 15 | (2.3) | 10 | (1.6) | |
| Conditioning regimen, no. (%) | |||||
| Nonmyeloablative | 83 | (12.6) | 92 | (14.6) | .39 |
| Myeloablative | 541 | (82.3) | 499 | (79.3) | |
| NA | 33 | (5.0) | 38 | (6.0) | |
| HLA-DPB1 TCE mismatching, no. (%) | |||||
| Permissive | 566 | (90.7) | 388 | (61.7) | <.001 |
| Nonpermissive | 91 | (13.9) | 241 | (38.3) | |
| . | Patient mismatch HLA-DP group . | . | |||
|---|---|---|---|---|---|
| . | HLA-DP2 group (N = 657) . | HLA-DP5 group (N = 629) . | P . | ||
| Median patient age (range), y | 36 | (0-77) | 36 | (1-68) | .41 |
| Median donor age (range), y | 35 | (20-55) | 34 | (20-58) | .71 |
| Years of transplantation, no. (%) | |||||
| 1993-2000 | 204 | (31.1) | 197 | (31.3) | .92 |
| 2001-2005 | 247 | (37.6) | 230 | (36.6) | |
| 2006-2010 | 206 | (31.4) | 202 | (32.1) | |
| Patient-donor sex, no. (%) | |||||
| Male-male | 275 | (41.9) | 269 | (42.8) | .62 |
| Female-female | 115 | (17.5) | 109 | (17.3) | |
| Male-female | 167 | (25.4) | 143 | (22.7) | |
| Female-male | 100 | (15.2) | 108 | (17.2) | |
| Disease, no. (%) | |||||
| ALL | 201 | (30.6) | 189 | (30.0) | .99 |
| AML | 282 | (42.9) | 269 | (42.8) | |
| MDS | 85 | (12.9) | 82 | (13.0) | |
| CML | 89 | (13.5) | 89 | (14.1) | |
| Leukemia risk, no. (%) | |||||
| Standard | 383 | (58.3) | 324 | (51.5) | .05 |
| High | 242 | (36.8) | 272 | (43.2) | |
| Other | 32 | (4.9) | 33 | (5.2) | |
| GVHD prophylaxis, no. (%) | |||||
| Cyclosporine based | 294 | (44.7) | 294 | (46.7) | .56 |
| Tacrolimus based | 348 | (53.0) | 325 | (51.7) | |
| Other | 15 | (2.3) | 10 | (1.6) | |
| Conditioning regimen, no. (%) | |||||
| Nonmyeloablative | 83 | (12.6) | 92 | (14.6) | .39 |
| Myeloablative | 541 | (82.3) | 499 | (79.3) | |
| NA | 33 | (5.0) | 38 | (6.0) | |
| HLA-DPB1 TCE mismatching, no. (%) | |||||
| Permissive | 566 | (90.7) | 388 | (61.7) | <.001 |
| Nonpermissive | 91 | (13.9) | 241 | (38.3) | |
Leukemia risk: standard risk indicates the first or second complete remission of AML; first complete remission of ALL; and first chronic phase of CML, refractory anemia, and refractory anemia with ringed sideroblasts. Advanced risk indicates all other leukemias. Conditioning regimen: Myeloablative regimen indicates conditioning regimens with total body irradiation >8 Gy, oral busulfan ≥9 mg/kg, intravenous busulfan ≥7.2 mg/kg, or melphalan >140 mg/m2; reduced-intensity regimen indicates all other conditioning regimens.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NA, not available.